Incidence and risk factors for paclitaxel hypersensitivity during ovarian cancer chemotherapy-Reference-Cited by-同舟云学术

登录注册会员服务联系我们

Incidence and risk factors for paclitaxel hypersensitivity during ovarian cancer chemotherapy

Published:2005-03-25 Issue:1 Volume:56 Page:91-96
ISSN:0344-5704
Container-title:Cancer Chemotherapy and Pharmacology
language:en
Short-container-title:Cancer Chemother Pharmacol

Author:

Sendo Toshiaki,Sakai Naoko,Itoh Yoshinori,Ikesue Hiroaki,Kobayashi Hiroaki,Hirakawa Toshio,Nakano Hitoo,Oishi Ryozo

Publisher

Springer Science and Business Media LLC

Subject

Pharmacology (medical),Cancer Research,Pharmacology,Toxicology,Oncology

Link

http://link.springer.com/content/pdf/10.1007/s00280-004-0924-9.pdf

Reference42 articles.

1. Bitton RJ, Figg WD, Reed E (1995) A preliminary risk-benefit assessment of paclitaxel. Drug Saf 12:196–208

2. Boehm DK, Maksymiuk AW (1996) Paclitaxel premedication regimens. J Natl Cancer Inst 88:463–465

3. Bookman MA, Kloth DD, Kover PE, Smolinski S, Ozols RF (1997) Short-course intravenous prophylaxis for paclitaxel related hypersensitivity reactions. Ann Oncol 8:611–614

4. Calvert AH, Newell DR, Gumbrell LA, O’Reilly S, Burnell M, Boxall FE, Siddik ZH, Judson IR, Gore ME, Wiltshaw E (1989) Carboplatin dosage: prospective evaluation of a simple formula based on renal function. J Clin Oncol 7:1748–1756

5. Cantu MG, Buda A, Parma G, Rossi R, Floriani I, Bonazzi C, Dell’Anna T, Torri V, Colombo N (2002) Randomized controlled trial of single-agent paclitaxel versus cyclophosphamide, doxorubicin, and cisplatin in patients with recurrent ovarian cancer who responded to first-line platinum-based regimens. J Clin Oncol 20:1232–1237

Cited by 30 articles. 订阅此论文施引文献订阅此论文施引文献，注册后可以免费订阅5篇论文的施引文献，订阅后可以查看论文全部施引文献

1. Is a low dose of dexamethasone sufficient to prevent paclitaxel-related hypersensitivity reactions? A retrospective study in patients with gynecologic malignancy;Expert Review of Clinical Pharmacology;2024-04-23

2. Management of Patients with Hypersensitivity to Platinum Salts and Taxane in Gynecological Cancers: A Cross-Sectional Study by the European Network of Young Gynaecologic Oncologists (ENYGO);Cancers;2024-03-14

3. Management of infusion-related reactions in cancer therapy: strategies and challenges;ESMO Open;2024-03

4. Desensitization in patients with hypersensitivity to platinum and taxane in gynecological cancers;Cancer Medicine;2023-12-22

5. Hypersensitivity Reactions to Taxanes: A Comprehensive and Systematic Review of the Efficacy and Safety of Desensitization;Clinical Reviews in Allergy & Immunology;2023-08-17

同舟云学术

1.学者识别学者识别

2.学术分析学术分析

3.人才评估人才评估

"同舟云学术"是以全球学者为主线，采集、加工和组织学术论文而形成的新型学术文献查询和分析系统，可以对全球学者进行文献检索和人才价值评估。用户可以通过关注某些学科领域的顶尖人物而持续追踪该领域的学科进展和研究前沿。经过近期的数据扩容，当前同舟云学术共收录了国内外主流学术期刊6万余种，收集的期刊论文及会议论文总量共计约1.5亿篇，并以每天添加12000余篇中外论文的速度递增。我们也可以为用户提供个性化、定制化的学者数据。欢迎来电咨询！咨询电话：010-8811{复制后删除}0370

www.globalauthorid.com

TOP

Copyright © 2019-2024 北京同舟云网络信息技术有限公司
京公网安备11010802033243号京ICP备18003416号-3